scispace - formally typeset
H

Hiroaki Kajiyama

Researcher at Nagoya University

Publications -  388
Citations -  10270

Hiroaki Kajiyama is an academic researcher from Nagoya University. The author has contributed to research in topics: Medicine & Ovarian cancer. The author has an hindex of 49, co-authored 333 publications receiving 8535 citations.

Papers
More filters
Journal ArticleDOI

Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells

TL;DR: There is a possible link between chronic paclitaxel-resistance and induction of the EMT in EOC cells, and therapeutic benefits such as the restoration of chemosensitivity or suppression of metastasis will be enabled by gaining further insight into the mechanisms underlying chemoresistance and EMT.
Journal ArticleDOI

Effect of Indirect Nonequilibrium Atmospheric Pressure Plasma on Anti-Proliferative Activity against Chronic Chemo-Resistant Ovarian Cancer Cells In Vitro and In Vivo

TL;DR: It is demonstrated that plasma-activated medium also had an anti-tumor effect on chemo-resistant cells in vitro and in vivo and may contribute to a better patient prognosis in the future.
Journal ArticleDOI

Plasma-Activated Medium Selectively Kills Glioblastoma Brain Tumor Cells by Down-Regulating a Survival Signaling Molecule, AKT Kinase

TL;DR: PAM downregulated the expression of AKT kinase, a marker molecule in a survival signal transduction pathway, which suggests that PAM may be a promising tool for therapy of glioblastoma brain tumors by downregulating the survival signals in cancers.
Journal ArticleDOI

Selective killing of ovarian cancer cells through induction of apoptosis by nonequilibrium atmospheric pressure plasma

TL;DR: Flow cytometry and western blot analysis showed that plasma treatment of ovarian cancer cells induced apoptosis, and nonequilibrium atmospheric pressure plasma could be a promising tool for therapy for ovarian cancers.
Journal ArticleDOI

Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer.

TL;DR: The results indicated that the high IDO expression was involved in the progression of endometrial cancer and correlated with the impaired clinical outcome, suggesting that IDO is a novel and reliable prognostic indicator for endometricrial cancer.